Evidence map›Paper›PMID 40924376›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.

Giuseppa Scandurra, Filippo Marano, Vittorio Gebbia, Maria Rosaria Valerio, Daniela Sambataro, Valentina Lombardo, Giuseppe Angelico, Paolo Scollo, Giuseppe Scibilia, Alessandra Pizzo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giuseppa ScandurraOncology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Filippo MaranoOphthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Vittorio GebbiaMedicine and Surgery, Kore University, 94100, Enna, Italy.
Maria Rosaria ValerioMedicine and Surgery, Kore University, 94100, Enna, Italy.
Daniela SambataroMedicine and Surgery, Kore University, 94100, Enna, Italy.
Valentina LombardoMedicine and Surgery, Kore University, 94100, Enna, Italy. lombardovalentina89@gmail.com.ORCID http://orcid.org/0000-0002-0446-6436
Giuseppe AngelicoMedicine and Surgery, Kore University, 94100, Enna, Italy.
Paolo ScolloMedicine and Surgery, Kore University, 94100, Enna, Italy.
Giuseppe ScibiliaMedicine and Surgery, Kore University, 94100, Enna, Italy.
Alessandra PizzoOphthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life. This review summarizes current evidence on the incidence, pathophysiology, and clinical presentation of ADC-related ocular adverse events in gynecologic oncology. It also provides practical, evidence-based strategies for the prevention, monitoring, and management of these adverse events. Interventions include prophylactic topical therapies, supportive care measures, treatment delays or dose modifications, and herpes zoster vaccination. Comprehensive management of ocular toxicities is essential to ensure the safe and sustained use of ADCs, preserving both therapeutic benefit and patient well-being. Further research is warranted to optimize preventive and management protocols.

Indexed as

Eye DiseasesGenital Neoplasms, FemaleImmunoconjugatesAntibodies, Monoclonal, HumanizedFemaleHumansMaytansineAntibodies, Monoclonal, HumanizedImmunoconjugatesMaytansinemirvetuximab soravtansineAntibody–drug conjugatesGynecologic cancersMirvetuximab soravtansineOcular toxicityPrevention and managementTisotumab vedotin

Identifiers

PMID40924376

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.